chrisvoncsefalvay/vaers-outcomes huggingface dataset:
pain in arm; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (pain in arm) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (pain in arm). At the time of the report, PAIN IN EXTREMITY (pain in arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
I started getting symptoms sniffing and sneezing like a cold. At first the symptoms were light. Then the next day my symptoms progressed and I felt worse with runny nose, head congestion, headaches, mucous, and dry cough. I took an at home COVID-19 test which was negative. My wife had COVID-19 at that time. So I contacted my doctor and Friday morning I took a COVID PCR test which was positive and I also took another COVID-19 home test which was positive. I did a telehealth visit with my doctor and took vitals. I was prescribed Mon Lupardiar which helped with the symptoms almost instantly. I felt more normal after that and I finished that prescription yesterday. I only have sniffling and runny nose at the moment.
Increased intense Asthma events, new inhaler (Albuterol) prescribed and used for 3 days, Some vertigo, occasional body temperature fluctuation & SEVERE CHRONIC BRONCHITIS & intense coughing for over a week! - Tessalon Perles, NettiPot rinse routine 3x's/day, Flonase 3-4X's/day, Salt Solution oral & throat rinse, Tylenol & inhaler as needed.  Very stressful & scary/unpleasant.  I have very minimal confidence in injection repercussions now.
Covid vaccine monitoring documentation.  PT admitted 11/26/21 ? 11/30/21. POC SARS COV2 ANTIGEN POS 11/30/21. PT received dose 1 Moderna 2/4/21 Lot 013M20A. Dose 2 Moderna on 3/4/21 Lot 030M20A. PT currently admitted. PT documented to have covid-19 pneumonia with escalating oxygen requirements.
Varicella vaccine given yesterday (4/6/17). Croup and fever same night.
No adverse event; Vaccine Bivalent on 17Feb2023 but they realized the patient already received a previous Moderna Bivalent on 11Nov2022. This spontaneous case was reported by another health care professional and describes the occurrence of EXTRA DOSE ADMINISTERED (Vaccine Bivalent on 17Feb2023 but they realized the patient already received a previous Moderna Bivalent on 11Nov2022.) and NO ADVERSE EVENT (No adverse event) in a 57-year-old patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch nos. AS7146B and 050D22A) for COVID-19 prophylaxis.     Question:Describe relevant medical history/conditions, allergy, concomitant diseases and risk factor.Answer:HCP stated patient seemed to have a long medical history, but at this time she had to attend another patients, so Moderna could follow up later if needed.  Previously administered products included for COVID-19 prophylaxis: Moderna COVID-19 Vaccine (Dose 1, Lot number -017B21A) on 31-Mar-2021, Moderna COVID-19 Vaccine (Dose 2, Lot number -014C21A) on 28-Apr-2021, Moderna COVID-19 Vaccine (1st booster and Lot number-058H21A) on 21-Dec-2021. Past adverse reactions to the above products included No adverse event with Moderna COVID-19 Vaccine, Moderna COVID-19 Vaccine and Moderna COVID-19 Vaccine.   On 11-Nov-2022, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 17-Feb-2023, received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) dosage was changed to .5 milliliter. On 17-Feb-2023, the patient experienced EXTRA DOSE ADMINISTERED (Vaccine Bivalent on 17Feb2023 but they realized the patient already received a previous Moderna Bivalent on 11Nov2022.). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXTRA DOSE ADMINISTERED (Vaccine Bivalent on 17Feb2023 but they realized the patient already received a previous Moderna Bivalent on 11Nov2022.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXTRA DOSE ADMINISTERED (Vaccine Bivalent on 17Feb2023 but they realized the patient already received a previous Moderna Bivalent on 11Nov2022.).    No concomitant medication details was reported.  Patient did not receive any other vaccines in the 4 weeks prior to COVID-19 vaccine. HCP stated she was not sure if the medical assistant knew it was the bivalent and not the monovalent. There were no signs or symptoms currently shown via observation.  No treatment medication details was reported.
This spontaneous report was received from a physician and from a support services director via company representatives and refers to a patient of an unknown age and gender. The patient's pertinent medical history, drug reactions or allergies and concomitant medications were not reported. On 08-OCT-2015, the patient was vaccinated with a dose of an improperly stored GARDASIL 9 (strength: 0.5 ml) lot # L014198 and expiration date: 05-SEP-2017 (dose, anatomical location and route of administration were not reported). No adverse effects were reported. The dose of the vaccine was exposed to different temperature excursions (date unspecified): lasting for 120, and 144 hours, with the lowest recorded temperature of 34, and 33 degrees Fahrenheit (1.11, and 0.55 degrees Celsius) respectively. The vaccine was stored in a refrigerator. There was no product quality complaint involved. This is one of several reports received from the same reporter. Additional information has been requested.
I had muscle aches and then a headache, nausea, vomitting and developed Bell's Palsy
3 hrs after 1st vaccine developed bad headache, lasted about 36 hrs and then completely resolved.  12 hrs after 2nd vaccine, same headache last about 24 hrs then completely resolved Feb 28 same headache suddenly redeveloped and have been chronic since that time along with new dx of HTN.  Seen by doctor 2 times and ER that did CT of head/EKG/labs all normal so final discharge dx was migraines with HTN. I have never had headaches or HTN in my past medical history. Rx Lisinopril 10mg and Medrol 6 day dose pack have done little to relieve these symtoms.
numbing; tingly; This is a spontaneous report from a contactable Other HCP (patient).   A 55-year-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route of administration, administered in right arm on 20Mar2021 at 18:00 (at the age of 55-years-old) as dose 1, single, and second dose via an unspecified route of administration, administered in right arm on 09Apr2021 (at the age of 55-years-old) as dose 2, single for covid-19 immunisation.  Medical history included COVID-19 and asthma (post-covid still a problem). The patient had no known allergies. The patient received unspecified consoncitant drugs in two weeks. The patient experienced within 10 minutes mild numbing from the injection site on her upper left arm to her cheekbone-only on the left. Another way of describing is her upper left chest and shoulder through the lower left quadrant of her face (as reported). The most significant symptom the patient first noticed initially was that the left side of her nose and upper lips felt numb and tingly, but no other part of her face. The same reaction occurred in the same area of her body, but on the right side when she received the second dose on 09Apr2021. The patient prepared by taking Benedryl for the second dose, as per advice from an infectious disease physician she consulted prior to receiving the vaccine, so she felt the second dose reaction seemed more mild. She also was prepared having gone through the first vaccine. MD's who attended to her when she initially reported the first side effect had never heard of it, while the pharmacist who delivered the second dose had many times. The events resulted in Emergency room/department or urgent care. The patient did not receive treatment for events (as reported). The patient underwent lab tests and procedures which included sars-cov-2 test (Nasal Swab): negative on 02Jun2021. The outcome of events was recovered.   The lot number for BNT162b2 was not provided and will be requested during follow up.
Around 11am, same day as the vaccine, he started to get warm, by 1pm he had a 102F fever. He was given Ibuprofen, and continued to receive ibuprofen, every 6 hours for a couple days. The fever maxed at 105, and continued to spike unless he had the ibuprofen. Very diminished appetite, very fatigued.
Acute Hypoxemic, Hypercapnic Respiratory Failure, resolved - Secondary to bilateral PEs and COVID-19 infection below, on room air at baseline - 1/28 VBG: pH 7.41, pCO2 37.7, pO2 50, HCO3 24.0 - Weaned to room air with treatment as below     Intermediate-Low Risk Pulmonary Embolism - Bilateral LE DVTs below with elevated troponin's and evidence of right heart strain on imaging,  PESI: 117, Class IV, High Risk - 1/28 CT PA large PE within bilateral main pulmonary arteries of all lung lobes, evidence of right heart strain, pulmonary artery enlarged, moderate leukocytosis - 1/29 TTE normal RV dimensions and function, possible pulmonary hypertension - Peripheral Vascular followed, transitioned to Xarelto, follow up with PV in 1 month as outpatient   Bilateral Lower Extremity DVTs - In the setting of hypercoagulable state secondary to COVID-19 infection - 1/28 LE dopplers: DVT in left gastrocnemius, DVTs reaching as superiorly as popliteal vein on the right - Continue anticoagulation per above   COVID-19 Infection Community Acquired Pneumonia  - Patient denies any symptoms or sick contacts, received 3 vaccines (uncertain which ones) - 1/28 COVID-19 PCR positive, CT PA focal consolidation bilateral lower lobes, regional area groundglass opacity in right lower lobe, moderate leukocytosis - S/p ceftriaxone 1/29, azithromycin (1/29-1/30) and decadron 6 mg (1/28-1/30) - Will complete 4 days of po Augmentin for treatment of CAP   Paroxysmal Atrial Fibrillation with RVR - Likely secondary to heart strain due to PE, per patient no history of atrial fibrillation - 1/28 EKG may have been sinus rhythm with frequent PACs causing confusion for atrial fibrillation - CHADS-VASc = 4 - Will be discharged on Xarelto as above with outpatient follow-up with peripheral vascular   Elevated Troponin - Most likely Type II Demand Ischemia in setting of PE above - Trop 51 -> 45, negative delta   Leukocytosis, resolving - Reactive in setting of above - WBC 20.77 on admission decreased to 17K on discharge - Repeat CBC in 1 week   HF recovered EF - 4/22/21 TTE LVEF 20-25% - 1/29/23 TTE LVEF 61% - Home medication: losartan 25 mg daily - Consider escalating therapy with addition of beta blocker and SGLT2 inhibitor
Within 24 hours, son began to complain that he itched, especially head and neck. About 12 hours after that, he developed rash on face and neck, and both became very swollen. Then rash spread to extremities and abdomen. Lasted 10 days or so. Used BENADRYL, but he was very uncomfortable.
Arm pain; Muscle aches; Fatigue; Headache; This is a spontaneous report received from a contactable consumer, the patient. A 45-years-old non-pregnant female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955] via an unspecified route of administration in left arm on 24Mar2021, at 09:00, (at the age of 45 years-old) as a single dose, for COVID-19 immunisation. Medical history included hypothyroidism, gastroesophageal reflux disease (GERD), migraines, eczema, environmental allergies and seasonal allergies, since unknown dates. The concomitant medications included rt (MANUFACTURER UNKNOWN), levothyroxine sodium (SYNTHROID), esomeprazole magnesium (NEXIUM), azelastine hydrochloride; fluticasone propionate (DYMISTA), all on unknown dates taken for unknown indication and injection alave (MANUFACTURER UNKNOWN) taken for allergy. The patient previously took her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3247] via an unspecified route of administration on 02Mar2021, at 10:00, (at the age of 45 years-old) as a single dose, for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Mar2021 at 20:00, the patient had experienced local events very minor arm pain (pain in arm), systemic events minor muscle aches (muscle ache), mild fatigue (fatigue) and moderate headache (headache). The patient marked, selected not recovered because she still had mild fatigue, muscle aches and a mild (versus previously moderate) headache, but they were improving at the time of this report which was approximately 17 hours post onset. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No treatment was received for the events. The clinical outcome of events pain in arm, muscle ache, fatigue and headache were not recovered at the time of report.   No follow-up attempts are needed. No further information is expected.
This spontaneous report as received from a healthcare worker via field representative refers to a 15 year old female patient. The patient's pertinent medical history was none. Approximately in 2014 (reported as 2 years ago), the patient was vaccinated with GARDASIL 9 (lot # L016429; expiry date: 09-AUG-2017). Concomitant medications were none. On 03-FEB-2016, the patient felt light headed or dizzy. The patient's blood pressure was 98/40 (units not reported) and the patient was kept in the office until her blood pressure was normal. The patient sought medical attention and no treatment was provided for the events. The outcome of the events was recovered on an unspecified date in February 2016. The causality of the reported events was not reported. Additional information has been requested.
Pt had TYLENOL 1 1/2 hrs before vaccine administered. Pt received another dose of TYLENOL at 3 pm, 7 pm and then fever of 104.4 (forehead) noted around 10:30 pm. Another dose of TYLENOL at midnight. Fever stayed higher than 102 all night. Broke in the morning 100.9. Pt saw FNP this morning. Continue TYLENOL q 6 hrs.
nosebleed; headache; malaise; This is a spontaneous report from a contactable consumer or other non healthcare professional. A 78 year old female patient received bnt162b2 (BNT162B2), dose 2 via an unspecified route of administration, administered in Arm Left on 10Feb2021 15:45 (Batch/Lot Number: EL3302) as DOSE 2, SINGLE for covid-19 immunisation. Medical history included multiple sclerosis from an unknown date and unknown if ongoing , rheumatoid arthritis from an unknown date and unknown if ongoing , hypertension from an unknown date and unknown if ongoing , hyperlipidaemia from an unknown date and unknown if ongoing , urinary incontinence from an unknown date and unknown if ongoing , back pain from an unknown date and unknown if ongoing , myalgia from an unknown date and unknown if ongoing , hypersensitivity from an unknown date and unknown if ongoing.     The patient experienced nosebleed, headache and malaise on 11Feb2021 09:30 with outcome of unknown.  No follow-up attempts are possible. No further information is expected.
Received first Anthrax shot on 18 Nov 1999. Had local reaction to vaccination, redness,swelling and pain at shot site which eventually turned hard for several weeks.  Began having fever, chills, sweats and congestion, constant fatigue and by the end of November 1999 had constant abdominal pain and nausea. A noticeable change in general health. Change in eating habits as a result of not tolerating most usual food. Constipation, with hard and darker irregular bowel movements with mucous present in stool. finally went to the Doctor in February of 2000 for symptoms. Prescribed Robitussin, Ducoulax(?), Sudafed and Allegra. Off flight status for 1 week. Received second Anthrax shot on 20 Jan 2000.  Returned to doctor on 5 APR 2000. Abdominal pain getting worse, continued constipation and irregular bowel.  Labs from February normal.  Not officially diagnosed with anything. Over the last couple years since then I have lived with constipation, abdominal pain, fatigue and have experienced increasing memory loss and inability to concentrate. In 2002, experienced recurring lower back pain, intestinal disaccharidase deficiencies and malabsorption. Unexplained acute joint and bone pain in legs and chest, Overall resulting in about 1-2 weeks of being unable to perform normal duties.
Fever; extreme weakness; extreme tiredness;  injection site warm, swollen, reddened, painful for 72 hrs
Headache for seven days, chills for seven days body aches for three days, rash at injection site beginning on day 8.
Severe abdominal pain; bloating; belching; indigestion/Can not digest most fruit and vegetables except a little cooked spinach, boiled potato or yam and rice. Unable to eat poultry, meat, fish or egg.; Unable to eat; loss of appetite; This is a spontaneous report received from a contactable consumer (patient). A 60-year-old non-pregnant female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: EN6205) via an unspecified route of administration in left arm on 07Mar2021 at 14:00 (at the age of 60-year-old) as single dose for COVID-19 immunization. Medical history of the patient included blood pressure, diabetes, elevated cholesterol. Patient was taking other medications/concomitant [unspecified] within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient has not been tested for COVID-19. Patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: EL9266) via an unspecified route of administration in left arm on 24Feb2021 at 14:30 as single dose for COVID-19 immunization. On 21Mar2021, the patient experienced severe abdominal pain, bloating, belching, indigestion, unable to eat, loss of appetite. Patient was not able to digest most fruit and vegetables except a little cooked spinach, boiled potato or yam and rice and was unable to eat poultry, meat, fish or egg, survived a few days by eating Cheerios only. The problem was continuing for 5 weeks and medicine prescribed by doctors (primary care and Gastroenterologist) did not help. X-Ray, Ultrasound exam, computerized tomography (CT) Scan, Endoscopy failed to detect any abnormality on an unspecified date. Results of tests and procedures for investigation of the patient included: Nasal Swab with result: Negative on 20Apr2021. The adverse events result in Emergency room/department or urgent care. Patient was being treated for gastric problems in response to the adverse event. Outcome of the events were not resolved.   No follow-up attempts are needed. No further information expected.
This spontaneous report was received from a pharmacist regarding a patient of unknown age and gender. Information on the concurrent condition, medical history and pertinent drug allergies of the patient were not reported. On 08-DEC-2015 at time- 08:00, the patient was vaccinated with improperly stored RECOMBIVAX HB lot # L025738 (expiry date, dose #, route, dose units and anatomical location were not specified). Concomitant medication was not reported. No adverse events were reported. The high temperature and low temperature at which the product was stored were 5.6 and 1. 4 (units unspecified). There were no Product Quality Complaint (PQC) involved. This is one of several reports received from same reporter. Additional information has been requested.
Swollen lymph nodes at various times over 2 weeks. Consistent, intermittent headaches. Lethargy.; Consistent, intermittent headaches; Swollen lymph nodes at various times over 2 weeks. Consistent, intermittent headaches. Lethargy.; This is a spontaneous report from a contactable nurse (patient). A 36-year-old female patient received the first dose of BNT162B2 Lot number=EL1284, via an unspecified route of administration on 22Dec2020 11:15 at single dose in the left arm for COVID-19 immunization. Medical history included Allergies to Penicillin. Concomitant medication included melatonin, diphenhydramine hydrochloride (BENADRYL) and celecoxib (CELEXA). On 21Dec2020 19:00 (pending clarification), the patient experienced swollen lymph nodes at various times over 2 weeks, consistent, intermittent headaches and lethargy. The patient did not receive any treatment for the events. The patient was not pregnant at the time of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. The patient underwent lab tests and procedures which included Nasal Swab: negative on 04Jan2021. The outcome of the events was unknown.
Patient arm got swollen and it was painful, she could not sleep, went to the ER next day and got Med.
Information has been received from a medical assistant concerning a now 62 year old female who was vaccinated with a dose of VARIVAX (Merck) (lot # 662447/1548X) instead of ZOSTAVAX (Merck) in December. No adverse effects were reported. Follow-up information received from a medical assistant stated that the patient was vaccinated with a dose of VARIVAX (Merck) instead of ZOSTAVAX (Merck) on 03-DEC-2009. The bottles did not look like and the boxes were different. It was reported that it was not the packaging but human error on her part. This is one of several reports received from the same source. Additional information is not expected.
Pain in the left calf; Muscle pains in thighs; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Pain in the left calf) and MYALGIA (Muscle pains in thighs) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 004F21A, 039K20A and 013C20A) for COVID-19 vaccination.     The patient's past medical history included Surgery (infection form dermatological surgery.).   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 22-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 24-Oct-2021, the patient experienced PAIN IN EXTREMITY (Pain in the left calf) and MYALGIA (Muscle pains in thighs). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (Pain in the left calf) and MYALGIA (Muscle pains in thighs) outcome was unknown.            Patient was taking antibiotic as concomitant medication.
HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 4/6/2022 ATHEROSCLEROSIS OF AORTA  HYPOXEMIA 4/15/2022 ATHEROSCLEROSIS OF AORTA